FEMY FEMASYS INC

Femasys Inc. to Participate in “The Post-Roe Fertility Journey” Panel Discussion at SXSW 2023

Femasys Inc. to Participate in “The Post-Roe Fertility Journey” Panel Discussion at SXSW 2023

ATLANTA, March 09, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, announced today that Kathy Lee-Sepsick, founder, president & chief executive officer, will participate in the South By Southwest (SXSW) 2023 Conference being held in Austin, Texas from March 10-19, 2023.

Kathy Lee-Sepsick will participate in a panel discussion titled “The Post-Roe Fertility Journey” on March 11, 2023 at 10:00 am CT, which will discuss what considerations are needed in women’s health for protection during fertility management and family building in the post-Roe era.

About Femasys

Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health. Its two lead product candidates are FemBloc® permanent birth control and FemaSeed® localized directional insemination for infertility. The Company’s products currently marketed in the United States, include FemVue® for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath™, an intrauterine catheter for selective evaluation of the fallopian tubes, and FemCerv®, an endocervical tissue sampler that is the first product of the technology platform for tissue sampling. To learn more, visit or follow us on and .

Contacts:

Investors

Chuck Padala

LifeSci Advisors, LLC



Femasys Inc.

Investor Contact:



Media Contact:





EN
09/03/2023

Underlying

FEMYFEMASYS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on FEMASYS INC

 PRESS RELEASE
Free
FEMY FEMASYS INC

Femasys Announces FemSperm™ Kit to Activate Gynecologists and Advance ...

Femasys Announces FemSperm™ Kit to Activate Gynecologists and Advance FemaSeed® Fertility Platform -- First in the FemSperm family, the Setup Kit enables gynecologists to offer FemaSeed directly, expanding access ahead of IVF and driving revenue growth -- ATLANTA, Aug. 21, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, today announced the introduction of its FemSperm Setup Kit, the first in a planned family of products designed to fully enable gynec...

August 21, 2025 1 EN
 PRESS RELEASE
Free
FEMY FEMASYS INC

Femasys Secures UK Regulatory Approval of FemBloc Permanent Birth Cont...

Femasys Secures UK Regulatory Approval of FemBloc Permanent Birth Control --Advances European commercialization strategy following CE mark approval-- ATLANTA, Aug. 20, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced that it received the Medicines and Healthcare products Regulatory Agency (MHRA) approval for its FemBloc Permanent Birth Control, which signifies the product has met the required standards for safety, quality, and effectivenes...

August 20, 2025 1 EN
 PRESS RELEASE
Free
FEMY FEMASYS INC

Femasys Announces Second Quarter Financial Results for 2025

Femasys Announces Second Quarter Financial Results for 2025 -- Continued Progress on Regulatory Approvals and Global Commercialization of Fertility Portfolio -- ATLANTA, Aug. 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its financial results for the second quarter of 2025. Corporate Highlights from 2Q 2025 to date Announced European Union Medical Device Regulation approval of FemBloc®, the first global regulatory endorsem...

August 8, 2025 1 EN
 PRESS RELEASE
Free
FEMY FEMASYS INC

Femasys Secures First European Order for FemBloc, Marking Strategic Mi...

Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion --Initiation of access to FemBloc, a revolutionary non-surgical permanent contraceptive, as global availability accelerates-- ATLANTA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its first commercial entry into Europe with an order of approximately $400,000 USD for FemBloc Permanent Birth Control in Spain, the first country with an e...

August 6, 2025 1 EN
 PRESS RELEASE
Free
FEMY FEMASYS INC

Femasys Achieves Australian and New Zealand Regulatory Approvals for F...

Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic -- Milestone expands global reach and reinforces commitment to accessible, first-line infertility solutions -- ATLANTA, July 01, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products announces the achievement of regulatory approvals in Australia and New Zealand f...

July 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch